文献速递核素与放射性配体治疗放射性药物与辐射防护

评估长效放射性标记生长抑素类似物177Lu-DOTA-EB-TATE在有和无氨基酸输注下的安全性、生物分布和剂量学

Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion.
PubMed 文献 · Clin Nucl Med · 2023-04-18

10例转移性神经内分泌肿瘤患者随机交叉分组,分别接受3.7 GBq 177Lu-DOTA-EB-TATE在有或无氨基酸输注条件下治疗,比较安全性、生物分布与剂量学。结果显示两种方式耐受良好,无4级血液毒性、无任何级别肾毒性,肾功能指标前后无显著差异;患者自身比较中,无氨基酸输注时全身有效剂量、肾脏有效剂量及肾脏滞留时间与有氨基酸输注相比均无显著差异。

要点

  • 177Lu-DOTA-EB-TATE 3.7 GBq在有或无氨基酸输注下均耐受良好,无4级血液毒性、无任何级别肾毒性。
  • 患者自身比较:无vs有氨基酸输注的全身有效剂量、肾脏有效剂量、肾脏滞留时间均无显著差异。
  • 作者认为无氨基酸输注时肾脏吸收剂量与滞留时间仅轻微升高且不影响肾功能,但需更大队列与长期随访进一步研究。

核心结论

  • 177Lu-DOTA-EB-TATE PRRT在有或无氨基酸输注下在神经内分泌肿瘤患者中均表现出良好的安全性。
  • 无氨基酸输注时肾脏吸收剂量与肾脏滞留时间呈可接受的轻度升高,且不影响肾功能。
  • 作者认为需在更大队列和长期随访中进一步研究。

研究设计与样本

  • 10例转移性神经内分泌肿瘤患者被随机分为2组,采用交叉随机设计评估氨基酸输注对肾脏摄取的影响。
  • A组第一周期接受3.7 GBq 177Lu-DOTA-EB-TATE无氨基酸输注,第二周期有氨基酸输注;B组第一周期有氨基酸输注,第二周期无氨基酸输注。
  • 所有患者在给药后1、24、96、168小时行系列全身平面显像,24小时行SPECT扫描;PRRT前2天行腹部CT用于SPECT/CT融合。
  • 剂量学采用HERMES软件计算,并进行组间和患者自身比较。

主要发现

  • 有或无氨基酸输注的177Lu-DOTA-EB-TATE给药均耐受良好,任何患者均未观察到4级血液毒性,1例报告3级血小板减少症,未记录到任何级别的肾毒性。
  • PRRT前后肌酐(75.1 ± 21.7 vs 67.5 ± 18.1 μmol/L,P = 0.128)、血尿素氮(4.5 ± 0.8 vs 5.1 ± 1.4 mmol/L,P = 0.612)、GFR(109.3 ± 25.2 vs 100.9 ± 24.9 mL/min,P = 0.398)均无显著差异。
  • 每个周期A组与B组之间全身有效剂量、肾脏有效剂量及肾脏滞留时间均无显著差异(P > 0.05)。
  • 患者自身比较:无vs有氨基酸输注的全身有效剂量(0.14 ± 0.05 vs 0.12 ± 0.04 mSv/MBq,P = 0.612)、肾脏有效剂量(1.09 ± 0.42 vs 0.73 ± 0.31 mSv/MBq,P = 0.093)、肾脏滞留时间(2.95 ± 1.58 vs 3.13 ± 1.11小时,P = 0.674)均无显著差异。

关键数值与推荐

  • 177Lu-DOTA-EB-TATE给药剂量为3.7 GBq。
  • 有或无氨基酸输注患者自身比较的肾脏有效剂量为1.09 ± 0.42 vs 0.73 ± 0.31 mSv/MBq(P = 0.093),未达统计学显著。
  • 有或无氨基酸输注患者自身比较的全身有效剂量为0.14 ± 0.05 vs 0.12 ± 0.04 mSv/MBq(P = 0.612),未达统计学显著。
  • 有或无氨基酸输注患者自身比较的肾脏滞留时间为2.95 ± 1.58 vs 3.13 ± 1.11小时(P = 0.674),未达统计学显著。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文结论指出需在更大队列中进一步研究并进行长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Kidney is considered to be one of the dose-limiting organs in peptide receptor radionuclide therapy (PRRT). Amino acid cocktail infusion has been applied to reduce renal absorbed dose by inhibiting the proximal tubular reabsorption of the radiopeptide. An Evans blue-modified 177 Lu-labeled octreotate ( 177 Lu-DOTA-EB-TATE) has an extended circulation in the blood, which may make the amino acid infusion unnecessary. The aim of this study was to evaluate the safety, biodistribution, and dosimetry of 177 Lu-DOTA-EB-TATE with and without amino acid infusion. PATIENTS AND METHODS: Ten patients with metastatic neuroendocrine tumors were randomly divided into 2 groups. The effect of amino acid infusion on renal uptake was assessed in a crossover randomized setting. Group A received 177 Lu-DOTA-EB-TATE at a dose of 3.7 GBq without amino acid infusion for the first cycle and with amino acid infusion for the second cycle; group B received 177 Lu-DOTA-EB-TATE at a dose of 3.7 GBq with amino acid infusion for the first cycle and without amino acid infusion for the second cycle. All patients underwent serial whole-body planar imaging at 1, 24, 96, and 168 hours and SPECT scan at 24 hours after radioligand administration. Abdominal CT was performed 2 days before PRRT for SPECT/CT fusion. The dosimetry was calculated using the HERMES software. Dosimetry evaluation was compared on a between-group and intrapatient basis. RESULTS: Administrations of 177 Lu-DOTA-EB-TATE with or without amino acids were well tolerated. No grade 4 hematotoxicity was observed in any of the patients. Grade 3 thrombocytopenia was reported in 1 patient. No nephrotoxicity of any grade was recorded. No significant difference was observed in creatinine (75.1 ± 21.7 vs 67.5 ± 18.1 μmol/L, P = 0.128), blood urea nitrogen (4.5 ± 0.8 vs 5.1 ± 1.4 mmol/L, P = 0.612), or GFR (109.3 ± 25.2 vs 100.9 ± 24.9 mL/min, P = 0.398) before and after PRRT. For each cycle, there was no significant difference in whole-body effective dose, kidney effective dose, as well as residence time of the kidneys between group A and B ( P > 0.05). By intrapatient comparison, without and with amino acid infusion also did not show significant difference in whole-body effective dose (0.14 ± 0.05 vs 0.12 ± 0.04 mSv/MBq, P = 0.612), kidney effective dose (1.09 ± 0.42 vs 0.73 ± 0.31 mSv/MBq, P = 0.093), and residence time of the kidneys (2.95 ± 1.58 vs 3.13 ± 1.11 hours, P = 0.674). CONCLUSIONS: 177 Lu-DOTA-EB-TATE PRRT with and without amino acid infusion demonstrated a favorable safety profile in neuroendocrine tumor patients. Administration of 177 Lu-DOTA-EB-TATE without amino acid infusion has acceptable slightly increased kidney absorbed dose and residence time of the kidneys, and does not affect kidney function. Further investigation in a larger cohort and long-term follow-up are warranted.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jiang Y, Liu Q, Wang G, et al. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE With and Without Amino Acid Infusion. Clin Nucl Med. 2023. PMID: 37075254. doi:10.1097/RLU.0000000000004642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。